Japanese P2 study shows potential of combined vaccine and steroid drug in castration resistant PCa

March 15, 2013

Multi-peptide vaccination therapy combined with the low-dose steroid drug dexamethasone shows promise in treating chemotherapy-naive castration resistant prostate cancer (CRPC) patients.

The study, which won the third prize for best abstract in oncology at the 28th European Association of Urology Congress held in Milan, Italy from 15 to 19 March, showed the promising benefit of this in patients who are chemotherapy-naive or those not yet exposed to specific antigens.

"Results of our randomized prospective study suggest that multi-peptide vaccination therapy in combination with low dose has the therapeutic potential as a safe and efficient option for chemotherapy-naïve CRPC patients," said lead study author Dr. Takahiro Kimura, of the Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan.

Since immunotherapy does not have a strong ability to decrease tumour burden, it is considerably difficult to evaluate the full extent of a significant with peptide vaccines, explained Kimura. "Taking this into consideration, the present evidence is promising," he said.

The researchers have previously developed MHC class-I restricted peptide vaccines for and carried out a phase 1 trial to assess safety and immunological evaluation. In the present study, Kimura and his colleagues conducted a randomized phase 2 study to evaluate the efficacy of peptide for chemotherapy naïve CRPC patients.

Early stage CRPC (PSA<10ng/ml) patients were randomized to two treatment groups; with low dose (1mg/day) dexamethasone (Dx), while the other group were given low dose Dx alone. The patients were vaccinated subcutaneously with 3 mg of selected peptides (max. 4 kinds) six times at two weeks interval. Dx 1mg/day p.o. was started on the first day of peptide vaccination. Toxicity assessment, immunological and clinical responses were investigated every three months. The primary endpoint of the study is progression-free survival including serum PSA.

Kimura said that although percentage PSA decline is the same in both vaccination/dexamethasone and dexamethasone alone group, PSA-PFS was significantly longer (p<0.0008) in the vaccination group.

"This means that the anti-tumour immune response may play an important role in suppressing . This using peptide vaccines is likely to be comparable as that from currently developed anti-androgenic agents such as abiraterone acetate, MDV3100," Kimura noted.

Castration resistant prostate cancer is a difficult patient group to manage since although a number of therapeutic modalities have been developed, none have lived up to the full expectations and treatment options remain limited.

Kimura added that although the concept of immunotherapy for cancer is not new, recent technological advances have opened new avenues to explore and optimize peptide-based immunotherapy.

"Since the anti-tumour effects of peptide vaccination are driven by different mechanisms as those from ADT and chemotherapy, we may circumvent many of the pitfalls experienced with the current therapies. We believe that this treatment approach will be key in order to achieve a breakthrough as a new therapeutic option for CRPC," he said.

More information: T. Kimura, et al., "Combination therapy of peptide vaccines and dexamethasone for chemotherapy naïve castration resistant prostate cancer - a randomized phase-2 study," Third Prize for the Best Abstract (Oncology); Abstract Nr: 98 (AM13-2502); 28th Annual EAU Congress, 15 to 19 March 2013; Milan, Italy

Related Stories

Cabozantinib active in castration-resistant prostate cancer

December 3, 2012

(HealthDay)—The orally bioavailable tyrosine kinase inhibitor cabozantinib (XL184) has clinical activity in men with castration-resistant prostate cancer (CRPC), according to a study published online Nov. 19 in the Journal ...

Recommended for you

Study reveals new insight into DNA repair

August 3, 2015

DNA double-strand breaks (DSBs) are the worst possible form of genetic malfunction that can cause cancer and resistance to therapy. New information published this week reveals more about why this occurs and how these breaks ...

Strange circular DNA may offer new way to detect cancers

July 30, 2015

Strange rings of DNA that exist outside chromosomes are distinct to the cell types that mistakenly produced them, researchers have discovered. The finding raises the tantalizing possibility that the rings could be used as ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.